Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term follow-up of etranacogene dezaparvovec in adult men with hemophilia B
NL-OMON60574Phase 3Active, not recruiting
- Sponsor
- CSL Behring
- Start
- Sep 2024
- Modality
- Gene Therapies, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of etranacogene dezaparvovec in hemophilia B (HB), sponsored by CSL Behring. Primary endpoints: Number of participants with serious adverse events and adverse events of special interest, Percentage of participants with serious adverse events and adverse events of special interest and 1 more. Started Sep 2024; status: active, not recruiting.
02
Drugs
etranacogene dezaparvovec
03
Conditions
hemophilia B (HB)
Beyond the preview
Go deeper on NL-OMON60574.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60574.